IRLAB Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-110.01	-83.13	-177.84	-113.41	51.78	Upgrade
Depreciation & Amortization	4.32	4.58	4.32	3.72	3.22	Upgrade
Other Amortization	-	-	-	0.26	0.26	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	0.8	-	Upgrade
Other Operating Activities	8.73	3.96	-	-	39.09	Upgrade
Change in Accounts Receivable	5.68	2.79	3.63	3.63	-12.81	Upgrade
Change in Other Net Operating Assets	36.06	6.21	5.04	-37.62	47.11	Upgrade
Operating Cash Flow	-55.22	-65.59	-164.85	-142.61	128.64	Upgrade
Capital Expenditures	-	-0.2	-0.29	-2.88	-0.71	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-0.5	-	Upgrade
Investing Cash Flow	-	-0.2	-0.29	-3.38	-0.71	Upgrade
Long-Term Debt Issued	18.8	25	27.28	-	-	Upgrade
Long-Term Debt Repaid	-19.95	-3.6	-3.61	-3.13	-2.87	Upgrade
Net Debt Issued (Repaid)	-1.15	21.4	23.68	-3.13	-2.87	Upgrade
Issuance of Common Stock	74.56	-	-	-	-	Upgrade
Other Financing Activities	-0	-	-	-	-0.18	Upgrade
Financing Cash Flow	73.41	21.4	23.68	-3.13	-3.05	Upgrade
Miscellaneous Cash Flow Adjustments	-	0	-	0	-	Upgrade
Net Cash Flow	18.19	-44.39	-141.47	-149.12	124.89	Upgrade
Free Cash Flow	-55.22	-65.79	-165.14	-145.49	127.93	Upgrade
Free Cash Flow Margin	-96.10%	-69.52%	-2908.47%	-237.97%	61.57%	Upgrade
Free Cash Flow Per Share	-0.82	-1.27	-3.18	-2.81	2.47	Upgrade
Cash Interest Paid	12.5	6.52	0.2	0.3	0.8	Upgrade
Levered Free Cash Flow	-22.29	-38.77	-99.98	-103.57	69.69	Upgrade
Unlevered Free Cash Flow	-11.04	-32.22	-99.86	-103.38	69.92	Upgrade
Change in Working Capital	41.74	9	8.67	-33.99	34.3	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.